Merck was the measure's worst performer, sinking 4.3% after ending one study
on the use of vorapaxar , one of its investigational cardiovascular
medicines, and limiting the use of the drug in another study to those who
had experienced a previous heart attack or peripheral arterial disease. http://finance.yahoo.com/news/Merck-Statement-on-Changes-to-bw-
